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Zusammenfassung der Arbeit 
Die HIV-Infektion ist eine ernstzunehmende Erkrankung, die nahezu 38 Millionen Menschen 
weltweit betrifft. Dank des Forschungsfortschrittes lässt sich die Infektion heutzutage mit einer 
kontinuierlichen hochaktiven antiretroviralen Therapie behandeln. Allerdings ist eine Heilung 
der Erkrankung bislang nicht möglich.         
Diese Arbeit untersuchte die Effekte einer Therapieintensivierung auf das Immunsystem von 
HIV Patienten der New Era Studie (NE). Hierbei wurden 5 antiretrovirale Medikamente über 
einen Zeitraum von mindestens 5 Jahren verabreicht mit dem Ziel langfristig eine funktionale 
Heilung der Infektion zu erreichen. Eine Gruppe erhielt das Therapieregime aus 5 
Medikamenten während der chronischen Phase der Infektion (CHI), wohingegen eine weitere 
Gruppe während der akuten Phase begann (PHI). Die Ergebnisse wurden zwischen diesen 
beiden Gruppen verglichen sowie mit weiteren HIV Gruppen. Darunter befanden sich Patienten 
mit einer fortgeschrittenen Infektion ("Progressor"), Patienten mit einem konventionellen 
Therapieansatz und "HIV Controller". Einerseits beschäftigte sich diese Arbeit mit dem Effekt 
der Behandlung auf die zwei Untergruppen der Myeloid-derived suppressor cells (MDSCs), 
nämlich den PMN-MDSC und M-MDSC. Andererseits wurde der Effekt von spezifischen 
CD8-T-Zell Antworten auf zwei HIV Proteine Gag und Nef untersucht. Außerdem wurden 
mögliche Korrelationen zwischen den immunsuppressiven Zellen und den HIV-spezifischen 
CD8-T-Zell Antworten überprüft. 
Interessanterweise waren die Ergebnisse für die MDSCs und die Immunantworten der NE 
Kohorte vergleichbar mit den Ergebnissen der Patienten unter konventionellem Therapieansatz. 
Daher konnte in diesem Zusammenhang kein Vorteil für die Intensivierung der Therapie 
gezeigt werden. Desweiteren konnte kein klarer Vorteil für die Patienten mit einem frühen 
Behandlungsbeginn aus den Ergebnissen interpretiert werden. Die antiretrovirale Therapie 
schien sich stärker auf die PMN-MDSC Untergruppe auszuwirken, da hier nahezu normale 
Level erreicht wurden. Dagegen war die Frequenz der M-MDSCs im Vergleich zu den 
gesunden Probanden signifikant erhöht. Obwohl MDSCs für ihre suppressive Funktion auf      
T-Zellen bekannt sind, konnten keine Korrelationen zwischen den zwei Untergruppen der 
MDSCs und den HIV-spezifischen CD8-T-Zellen gefunden werden. 
Die Level der MDSCs waren vergleichbar zwischen den NE Patienten und den Patienten unter 
einer konventionellen Therapie mit cART. Allerdings zeigten die NE Patienten überraschend 
breite CD8-T-Zell Antworten, was auf einen höheren Grad der Erhaltung des Immunsystems 





The HIV infection is a serious health burden that affects almost 38 million people worldwide. 
Thanks to extensive research, the infection has become manageable for patients under a 
continuous highly active antiretroviral treatment but a cure has not been found up to now. This 
thesis investigated the effects of treatment intensification on the immune system of HIV patients 
of the New Era Study (NE). This involved 5 antiretroviral drugs over a minimal duration of 5 
years with the long-term objective of reaching a functional cure of HIV. One subgroup received 
the 5-drug regimen during the chronic stage (CHI) whereas the other subgroup started during 
primary infection (PHI). Results were compared within the two NE subgroups and to other HIV 
groups, including progressors, patients under a conventional cART and natural controllers. On 
the one hand, this study focused on the effect of treatment on the two subsets of myeloid-derived 
suppressor cells (MDSCs), namely PMN-MDSC and M-MDSC. On the other hand, the effect 
on CD8 T cell responses specific to two proteins of HIV, Gag and Nef, was studied. Possible 
correlations between the immunosuppressive cells and the HIV-specific CD8 T cell responses 
were also tested. 
Intriguingly, the results for MDSCs and immune responses were similar in the NE cohort and 
patients under cART. Thus, it was not possible to postulate an advantage for the treatment 
intensification. Furthermore, a clear advantage for the patients with an early treatment start 
could not be interpreted from the results either. The impact of antiretroviral treatment appeared 
to be greater on the PMN-MDSC subset as it led to almost normal levels. In contrast, the 
frequency of M-MDSCs remained significantly higher in comparison to healthy individuals. 
Although MDSCs are known to exert their suppressive function on T cells, there were no 
correlations found between the two subsets of MDSCs and the HIV-specific CD8 T cells 
investigated.   
In the NE patients, the level of MDSCs was comparable to those of the conventional cART-
treated patients. However, NE patients revealed a surprisingly broad CD8 T cell response which 
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1.1  Milestones in the history of HIV 
The first isolation of the Human Immunodeficiency Virus (HIV) from a lymph node biopsy 
dates back to 1983. This finding led to the conclusion that HIV was the causative agent of the 
Acquired Immunodeficiency Syndrome (AIDS), a severe immune suppression which had 
previously been described as a new disease by the CDC in 1982. (1) Since its discovery, this 
virus has infected over 70 million people and over 32 million AIDS-related deaths have been 
reported worldwide (2). As a global burden for health and economics, HIV has drawn 
significant attention from the research community and has thereby become the most 
researched virus amongst all.  
In the first years after HIV discovery, an infection inevitably led to death after 8-10 years. Due 
to intensified research commitment over the past 35 years, it has been possible to develop an 
effective antiretroviral treatment for patients infected with HIV. Nowadays, HIV patients who 
consistently follow their treatment regimen can reach a life expectancy comparable to a non-
infected individual. One of the latest achievements in the recent years has been the 
establishment of an effective pre-exposure prophylaxis (PrEP) which reduces the chances for 
those who are at substantial risk of HIV infection to near-zero. Despite those major 
breakthroughs in HIV management, neither the attempts to find a cure for HIV infection nor 
a vaccine to prevent the transmission of HIV in the first place have been successful. It is 
therefore important to further study the virus in relation to its host in order to identify new 
approaches in terms of treating and curing HIV, respectively.  
1.2 The nature of the Human Immunodeficiency Virus 
1.2.1 Transmission routes of HIV 
HIV has rapidly evolved into a human pandemic spanning across all continents and different 
types of people. This was possible due to different routes of transmission including sexual 
transmission which accounts for the majority of reported HIV cases. However, in some parts 
of the world, particularly in Eastern and Southern Africa, vertical transmission from a HIV-
positive mother to her child is of great concern. (3) Another route of transmission is via blood, 
for example by sharing needles amongst drug users, and has increased the number of people 




1.2.2 Two Subtypes of HIV: HIV-1 and -2 
HIV is a lentivirus which is part of the family of retroviruses and can be classified into two 
major types, HIV-1 and HIV-2. An infection with the former is more common and responsible 
for the AIDS pandemic. Therefore HIV-1 will be the focus of this study. The latter is mostly 
found in West Africa. It significantly differs from HIV-1 in terms of its markedly reduced 
pathogenicity, slower disease progression and its response to the available treatment options. 
(5) 
1.2.3 The HIV Genome 
The genome of HIV-1 is comprised of three major structural genes which can also be found in 
other retroviruses: Gag (group specific antigen), Pol (polymerase) and Env (envelope). In 
addition, the genome is comprised of 4 accessory (Vif, Vpr, Vpu and Nef) and two regulatory 
genes (Tat and Rev) which are unique to HIV. The Gag gene codes for a precursor protein that 
is cleaved to several HIV proteins. Those are involved in HIV assembly and release. (6) Nef 
(negative factor) codes for a regulatory protein that enables the virus to easily replicate 
particularly in the early stages of infection by downregulating certain parts of the immune 
system of the host. (7) Due to their high immunogenicity, Gag and Nef are of great interest for 
this study. (8) 
Figure 1: Structure of the HIV-1 genome. 
Figure 1 schematically illustrates the organisation of the HIV-1 genome. (9) It is comprised of three structural 
genes (Gag, Pol and Env) as well as six regulatory and accessory genes (Vif, Vpr, Vpu, Tat, Rev and Nef). The 







1.2.4 The three stages in HIV infection 
The main cellular target of HIV is the CD4 T lymphocyte whose major function is to coordinate 
the immune response by regulating other immune cells which comprises among others the 
production of cytokines to the stimulation of B cell maturation and the activation of cytotoxic 
T cells. When untreated, the HIV infection ultimately leads to the depletion of CD4 T cells. The 
typical course of an untreated HIV infection is defined by different stages which can be referred 
to as acute, asymptomatic and AIDS as the final stage.  
Figure 2 shows a typical course of HIV infection during the acute and chronic stage regarding two clinical 
parameters, CD4 cell count and viral load. CD4 cell count is given in cells/mm3 on the left side whereas viral load 










After an individual has encountered HIV, the virus rapidly multiplies within the human body 
resulting in extremely high viral loads which lead to a greatly increased risk of transmission. 
The viral load inversely correlates with the CD4 cell count which drops during the acute 
phase and even falls below 200/µl. The acute/primary stage of infection takes up to 4 - 6 
weeks where the infected person often suffers from non-specific flu-like symptoms. This is 
followed by an asymptomatic stage in which the CD4 cell count usually recovers at least in 
part. This results in the control of the viral load at least for a certain period of time before it 
slowly starts to increase on a long term. This stage varies in length, though most people 
advance to the final stage within 6 – 8 years in the absence of antiretroviral treatment.  




Low CD4 cell counts are characteristic of this stage and show that the immune system has 
severely been damaged over the course of time. An array of opportunistic infections and 
cancers can be seen during this final stage which is better known as AIDS.  
1.3 Treating HIV: Success and limitations 
In 1996 the combination of highly antiretroviral drugs (HAART), nowadays referred to as 
combined antiretroviral therapy (cART), was introduced and revolutionised the treatment of 
HIV up to the present day. cART effectively reduces the viral load of the infected patient to 
an undetectable level of at least ≤ 50 copies/ml. Once considered a fatal illness, HIV has 
turned into a manageable condition given that treatment is applied for life. (11) 
Basically, cART consists of a combination of three drugs which interfere with specific steps 
in the viral life cycle. An integral part of a typical drug regimen are nucleoside reverse 
transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) that stop viral multiplication by blocking ‘reverse transcriptase’. Further drugs 
used in the regimen are protease inhibitors (PIs), integrase inhibitors (INIs) and entry 
inhibitors (EIs) named with regard to the step they interfere with in the viral life cycle. 
In order to prevent drug resistances, it is important to use at least two different drug classes 
at a time. (12) Furthermore, the patient needs to make sure that the prescribed drug regimen 
is strictly followed without allowing any pauses. Despite the continuous improvement of 
HIV drug agents, a major factor contributing to poor adherence still are the side effects 
caused by cART which can lead to a number of different long-term effects including 
hepatotoxicity, lipodystrophy or osteoporosis. (13) 
Since most HIV patients still get diagnosed in their early adulthood, an average HIV patient 
will need to receive cART for a significant amount of time, approximately 30 to 50 years. 
(14) The results of the START study (Strategic Timing of Antiretroviral Therapy) published 
in 2015 further emphasized that the earlier antiretroviral treatment was initiated the better 
the outcome for the patient. (15) Altogether, this puts an enormous financial burden on health 






1.4 New perspectives on Curing HIV 
To date, no cure for HIV has been found yet. In the past it has been difficult to target the 
virus in a way that allows full eradication from the human body. A major obstacle in the 
search for HIV eradication is that HIV latently resides in cells which are not detected by the 
immune system but have the ability of viral reactivation. These cells are memory CD4 T 
cells, can be found at different tissue sites and are collectively known as the HIV        
reservoir. (16) Besides a full viral eradication, another concept of curing HIV is referred to 
as ‘functional cure’. This describes a state in which the virus is kept under control by the 
immune system itself in the absence of antiretroviral drugs. 
This phenomenon has already been described in a small group of HIV-infected individuals 
which make up less than 1% of the HIV population. Those are HIV controllers which are 
characterised by low viral loads, normal CD4 T cell counts, show no clinical symptoms and do 
not progress to an advanced stage of infection even in the absence of treatment. On a cellular 
level, they typically exhibit broader HIV-specific T cell responses, reduced viral reservoirs and 
protective HLA alleles. (17) Although the determining factors leading to non-progression have 
not fully been identified, HIV controllers can certainly serve as a model in terms of a ‘functional 
cure’. (18) 
Investigating the concept of a ‘functional cure’ was further encouraged by the French 
VISCONTI study published in 2013. In this study, researchers identified 14 people who were 
able to control viremia after treatment interruption. They had received cART within the first 
weeks after transmission and had followed the drug regimen for approximately 3 years prior 
to treatment interruption. The results obtained during treatment interruption were surprising: 
the virus was detectable but significantly less than one would normally expect in untreated 
HIV patients (<400 copies/ml) and the CD4 cell count did not appear to be affected by the 
absence of cART. The results were kept stable for a prolonged period of time and there was 
no need to resume HIV treatment. Similarly surprising were the results from genetic testing 
performed on those 14 individuals. They revealed that the patients did not come from a 
favourable genetic background concerning the natural control of HIV, suggesting that other 
factors must have been responsible for the observed post-treatment control. One of them was 
the antiretroviral treatment initiated very early in the course of the infection. This might have 
limited the development of viral diversity and preserved the immune system from chronic 




1.5 Attempts towards a functional cure for HIV  
In the past years, eliminating viral reservoirs in HIV patients has increasingly been of 
scientific interest as they represent a significant barrier towards a cure for HIV. Although 
the exact timing is uncertain, viral reservoirs are believed to evolve within the first days to 
weeks after HIV transmission. Although even an early application of ART cannot block the 
establishment of the HIV reservoir, early ART appears to result in a reduced reservoir when 
compared to patients with a later ART start. (20; 21) HIV latently resides in different subsets 
of resting memory CD4 T cells for a substantial amount of time and is able to escape 
conventional HIV therapy. There are three main subsets of cells identified which serve as 
the cellular reservoir even over a prolonged period of ART. Amongst those cells are central, 
transitional and effector memory CD4 T cells which facilitate viral persistence via different 
mechanisms. (22) Once antiretroviral treatment is being paused, the cells get reactivated 
from their resting state and account for the quick and steep increase of viral replicates. 
Developing a strategy towards targeting those hidden reservoirs, could therefore bring us 
one step closer to the finding of a ‘functional cure’. (23) 
1.5.1 The New Era Study 
In 2009 the New Era Study was launched in Germany as an Investigator Initiated Trial (IIT) 
with the ultimate aim of eradicating HIV amongst study participants. This was performed by 
initiating a multi-drug class (MDC) regimen during the primary stage of infection. 20 primary 
infected patients (PHI) had to meet certain inclusion criteria including the presence of less than 
two bands in the Western blot analysis. In order to compare results from PHI, a second group 
of 20 chronic HIV patients (CHI) who had already been under cART for at least 36 months was 
recruited to follow the same MDC cART. Furthermore both groups, PHI and CHI, needed to 
have a CD4 cell count above 200 cells/ul. The intensified drug regimen included an integrase 
inhibitor (Raltegravir) and an entry inhibitor (Maraviroc) in addition to a conventional three 
drug cART which included a protease inhibitor. Based on previously performed calculations, 
researchers of the New Era study predicted that it would take at least 7 to 8 years of intensified 
treatment to eliminate latent reservoirs in their patients to possibly reach eradication of the 
virus. (24) 
During the course of the New Era Study, different laboratory parameters were repeatedly 
taken to monitor the current state of the participants. This included the measurement of cell-




Those measurements clearly showed the reduction of proviral DNA amongst participants. 
Nonetheless, post-treatment controllers of the VISONCTI Study showed that low proviral 
DNA is not a necessary prerequisite for post-treatment control, implying that other predictive 
factors needed to be taken into account. Following at least 5 years of intensified treatment, 
an array of additional immunological and viral parameters were investigated in the New Era 
study to identify markers which could possibly predict a successful post-treatment control. 
Amongst those were immunosuppressive cells, i.e. myeloid-derived suppressor cells, and 
CD8 T cell responses which were examined in this thesis.   
1.6 Myeloid-derived suppressor cells 
1.6.1 Characteristics of Myeloid-derived suppressor cells 
Exhaustion of the immune system plays an important role particularly during the advanced 
stage of HIV infection. It is characterised by a progressive loss of functions of immune cells 
including CD8 and CD4 T cells. Amongst other consequences, ‘immune exhaustion’ leads 
to a loss of CD8 T cells’ cytotoxic function disabling them to eliminate HIV. CD4 T cells 
lose their ability to produce cytokines which in turn is a crucial component in the activation 
of CD8 T cells. There are several molecules known to be involved in the chronic phase of 
HIV-1 leading to this phenomenon. Amongst others are PD-1, CTLA-4, LAG-3 and Tim-3. 
They lead to a downregulation of the process of immune activation. (25) In addition, cell 
populations that exhibit regulatory effects on immune cells are of great scientific interest. 
One of those cell populations are myeloid-derived suppressor cells (MDSC). They are a 
heterogeneous group of immature cells with a myeloid origin which can protect the healthy 
individual from an overt inflammatory response. Furthermore, they have an impact on tissue 
repair. Under certain pathological conditions such as infections, cancers and organ 
transplantations, different factors create an environment that disrupts the maturation of 
immune cells. In consequence, immature cells rise in numbers and gain certain 
immunosuppressive functions. This process is facilitated by cytokines such IL-6, IFN-
gamma and TNF-alpha during an infection with HIV. (26) Some pathogens and tumours are 
able to benefit from the regulatory effects of MDSCs and thus manage to escape the immune 
system response. Although MDSCs have been known and are being studied for more than 
20 years, a detailed understanding underlying their involvement in HIV 





Nowadays, MDSCs are not only of great scientific interest in areas such as cancer research 
but have become increasingly important in the field of infections. Despite extensive research 
on this specific cell type, study results appear to differ substantially. One factor contributing 
to this discrepancy in results is certainly the fact that MDSCs represent a vulnerable cell type 
that has been studied by different research teams with varying approaches. In 2016 Gruetzner 
et al showed that cryopreservation and the time of blood draw are essential when analysing 
MDSCs and differ between the two existing subsets of MDSCs. (28)  
Human MDSCs can be divided into two main subsets according to their distinct morphology 
and surface phenotype: polymorphonuclear (PMN) and monocytic (M) MDSCs. Their 
phenotype can be distinguished by flow-cytometry analysis. In the past, different study 
groups have used different sets of surface molecules to distinguish MDSCs which also 
contributed to the confusion in study results. The phenotype used for analysis in this study 
is CD14-, CD11b+, CD66b+/CD15+ for the PMN-MDSC whereas that of M-MDSC is 
defined as CD11b+, CD14+, HLA-DR-/low, CD15- and corresponds with current 
recommendations by Bronte et al. (29) 
1.6.2 Myeloid-derived suppressor cells during HIV infection  
Several studies of the past have focused on the investigation of MDSC frequencies at 
different stages of the HIV infection as well as the effect antiretroviral treatment has 
particularly on those cells. Despite intensive research in this field, findings of different study 
groups are inconsistent highlighting the need for further investigations. 
In an untreated infection, both subsets of MDSCs, PMN and M-MDSCs, are increased in 
HIV patients and their frequency correlates with the viral load. Corresponding to their 
immunosuppressive function, they also appear to correlate inversely with the CD4 cell count 
during an untreated HIV infection as well as with disease progression. (30; 31; 32) Moreover, 
PMN-MDSCs were shown to induce CD8 T cell proliferation in vitro whereas M-MDSCs 
were also shown to inhibit CD8 T cell function. (31; 32) The mechanisms used to suppress 
the immune system also appear to differ between the two MDSC subsets. (33; 34; 35) 
Previous studies have examined the effect of antiretroviral treatment on PMN-MDSC 
frequencies in HIV patients. In 2012 Vollbrecht et al showed that the increased levels of PMN-
MDSC in HIV progressors who were not under antiretroviral treatment decreased when cART 
was initiated. (31) Correspondingly, Wang et al showed that PMN-MDSCs were not detected 




Consistent with those results, Tumino et al found higher levels of PMN-MDSC in HIV patients 
when compared to healthy controls. However, they could not find a difference between HIV 
patients under cART and HIV progressors. (37) Contrastingly, a study by Zhang et al was able 
to find differences in PMN-MDSC frequencies between untreated and treated HIV patients. 
(38) In a recent study by Agrati et al, HIV patients were examined in their primary stage of 
infection and showed high levels of PMN-MDSC. Interestingly, these high levels of PMN-
MDSC were not found to be reduced after antiretroviral treatment had been applied for 48 
weeks. (39) Yet another study used SIV-infected macaques to examine the effect of 
antiretroviral treatment as well as treatment interruption on MDSCs. They found that MDSCs 
remained elevated over a 7-months course of cART. Upon treatment interruption, they reported 
a drastic increase in MDSC levels with the major fraction being PMN-MDSCs. (40)  
In terms of the dynamics of M-MDSCs during HIV infection, the results are similarly 
conflicting. In 2013 Quin et al demonstrated that M-MDSCs are dramatically increased in 
the peripheral blood of HIV patients in comparison to healthy controls. They also recorded 
a decrease in M-MDSC levels in HIV patients under treatment application for 84 weeks. 
However, the patients did not reach normal M-MDSC levels despite the treatment. (32) 
Correspondingly, Wang et al showed that M-MDSC levels were substantially higher in HIV 
patients than in healthy controls. This also applied to HIV patients under cART with 
undetectable levels of viremia. (36) Contrastingly, Vollbrecht et al also examined M-MDSCs 
in HIV patients and found no increase in M-MDSC levels amongst HIV progressors who 
were not under cART. (31) Overall, this emphasises the need for further research on the 
function and cellular behaviour of MDSCs and the need to clearly distinguish between the 
MDSC subsets. 
1.7 CD8 T cells 
1.7.2 The cytotoxic T cell response 
CD8 T lymphocytes, also called cytotoxic T lymphocytes (CTL), are a subpopulation of T 
cells and part of the adaptive immune system. Besides their clinical relevance in tumour 
immunology, they are effective in eliminating intracellular pathogens. Thus, CTLs play a 
crucial role in the control of HIV infection both during the acute and chronic stage. They 
recognise an infected cell via antigen presentation: An infected cell displays viral peptide 
fragments on its surface via the Major Histocompatibility Complex-1 (MHC-1), a peptide 




CTLs express specific T cell receptors which allow them to bind to only one specific epitope 
presented in the MHC-1 complex – including HIV-specific epitopes. The interaction 
between CTLs and the infected cell immediately triggers a cytotoxic response leading to the 
release of cytokines (TNF-α, IL-2) and the induction of apoptosis. As a result, viral 
replication is reduced and a decrease in viral load can be noted. A polyfunctional HIV-
specific CTL response that is characterised by displaying several effector functions 
simultaneously might be an important factor for successful control of HIV in HIV 
controllers. (41; 42) Nonetheless, the CTL response of most HIV patients does not result in 
a complete suppression of the virus and fails in terms of long-term infection control.  
1.7.3 Loss of function in CD8 T cells during HIV infection 
Several studies have described a progressive loss of function in CTLs during the course of 
the HIV infection. CTLs are able to fight HIV by incorporating multiple effector 
mechanisms. However, the impairment of these mechanisms contributes to the viral immune 
evasion. 
During the later stages of HIV infection, a persistence of HIV antigens will constantly keep 
CTLs activated. This is known as immune activation and is characterised by the higher 
expression of immune activation markers such as HLA-DR, CD38 and Ki-67 at the surface 
of the cell. (43) This constant activation of CTLs then leads to a phenomenon which is 
termed ‘immune exhaustion’ (see section 1.6.1). The cells gradually lose their ability to 
respond to HIV in the way they used to during earlier stages and there are multiple factors 
involved underlying this phenomenon. One study in 2006 compared HIV progressors to non-
progressors and found that it is not the mere quantity but rather the quality in functionality 
of CTLs that matters in terms of disease progression. (44)  
There is further evidence that the impaired function of CTLs observed over the course of the 
infection is also mediated by a change in expression of cellular surface receptors including 
PD-1, Tim-3 and CD160 which contribute to the exhaustion of the cell. (45) Buggert et al 
showed that transcription factors such as T-bet and Eomes which differentially regulate T 
cell exhaustion show an inverse expression during HIV infection when compared to the 






Interestingly, different studies were able to demonstrate that CTLs’ effector functions can at 
least be restored in part under antiretroviral treatment. (47; 48) Rehr et al compared chronic 
HIV patients during cART initiation and maintenance and found that polyfunctional CD8 T 
cells rise in numbers when the viral load decreases. (49) Upon treatment interruption this 
effect is however reversed. (50) 
1.7.4 Breadth and magnitude of the CD8 T cell response in HIV patients 
Due to their significant role in the control of HIV, CD8 T cells play a central role in curing HIV 
independent of the pursued strategy, either via a ‘functional cure’ or HIV eradication. They 
have also been considered as potential targets in the development of a vaccine. Nevertheless, 
the factors required for a vaccine of high efficacy are still to be found. Elite controllers are an 
interesting group of HIV patients to consider in this context as they are able to control viral 
replication in the absence of antiretroviral treatment. Besides low viremia, they express certain 
characteristics more commonly such as histocompatibility alleles, i.e. HLA-B57 and HLA-B27, 
but the underlying mechanisms contributing to the control of HIV are unclear. (51) There are 
two terms which can be used to describe the HIV-specific CD8 T cell response in relation to 
HIV epitopes: ‘Breadth’ is defined by the number of HIV epitopes targeted by the CD8 T cell 
response whereas ‘magnitude’ describes how strong the response is towards a certain epitope. 
In a study by Addo et al, two of the most frequently recognised HIV epitopes amongst HIV 
patients at different stages of infection were ‘p24 Gag’ and ‘Nef’. However, their breadth and 
magnitude appeared to vary greatly between the study participants. Interestingly, a previously 
proposed inverse correlation between both, breadth and magnitude, and viral load in plasma 
could not be confirmed in this study. Moreover, it has been shown that the application of 
antiretroviral treatment leads to a partial restoration of CD8 T cells even when treatment is 
initiated at a later stage of the infection. (52) Addo et al demonstrated lower and narrower 
responses in treated patients compared to an untreated cohort. Furthermore, an early initiation 
of treatment led to low breadth and magnitude. (53; 54) Finally, it is noteworthy that breadth 
and magnitude are only two possible ways of examining the HIV-specific CD8 T cell response 







1.8 Aims of the Study  
The New Era study comprised a cohort of HIV patients who had started a 5-drug antiretroviral 
therapy either during the acute or chronic stage of infection with the ultimate aim of HIV 
eradication. In order to investigate the impact of an early treatment initiation with a 5-drug 
cART on parts of the immune system of the HIV-infected patients, the parameters MDSCs and 
CD8 T cell responses were studied and compared to patients who were treated with a three drug 
ART, controllers, progressors and healthy controls. Prior to investigation, all New Era study 
participants had been taking 5-drug cART for at least 36 months. 
(1) The first aim of my thesis was to measure levels of MDSC in the New Era cohort from 
peripheral blood using flow cytometry. We hypothesised that reduced levels in both, PHI 
and CHI, could be seen due to the intensified treatment. We furthermore hypothesised that 
PHI had benefited from early treatment by resulting in lower levels of MDSC when 
compared to CHI. Since it is not clear to what extent the two subpopulations of MDSCs 
react to antiretroviral treatment, PMN-MDSCs and M-MDSCs were both measured in 
each study participant. 
(2) The second aim was to measure CD8 T cell responses from patients of the New Era cohort 
by the means of an interferon-gamma-based enzyme-linked immunospot assay (Elispot) 
in relation to the MDSC frequency. The two viral proteins of interest in this thesis were 
Gag and Nef as they had previously been recognized to be major targets of CD8 T cells.  
(3) The third aim was to compare the results of the New Era cohort with healthy controls 
as well as with other groups of HIV-infected individuals. Amongst those were HIV 
controllers, HIV patients under cART for at least 4 years and HIV progressors who 
were not under any antiretroviral treatment. 
Materials and Methods 
21 
 
2 Materials and Methods 
2.1 Materials 
2.1.1 Consumables and technical devices 
Cell counter, CASY®1 Model TT    Schärfe System, Reutlingen 
Cell Culture Flask, 6- und 24-well    PAA, Cölbe 
Cell Culture Flask, Filter, 25 und 75 cm²   TPP, Ibbenbüren 
Centrifuge 5810R      Eppendorf AG, Hamburg 
Centrifuge Tubes      TPP, Ibbenbüren 
Centrifuge, Sorvall Super T21    Thermo Scientific, Schwerte 
EDTA Monovette, KE/ 9ml     Sarstedt, Nümbrecht 
Elispot-Reader, ELR04     AID, Strassberg 
FACS Tubes       Becton Dickinson, Heidelberg 
Flow cytometer, FACSCalibur    BD, Heidelberg 
Freezing Container Mr. Frosty    Nalgene, Wiesbaden 
Heated Bath, Model 1083     GFL, Burgwedel 
Incubator, Heracell®      Heraeus, Hanau 
Microscope Dialux 20 EB     Leitz, Wetzlar 
Microscope Slides Kova    Hycor Biomedical, Kassel 
Model Labgard 437 Class II, Type A2   Plymouth, USA 
Multiscreen IP – 96 Well Elispot plate   Millipore, Schwalbach 
Nunc Cryo-Tubes 1,8 ml     Thermo Scientific, Langenselbold 
Safe-Lock Tubes 1,5 ml     Eppendorf AG, Hamburg 
Serological Disposable Pipettes, 5 and 10 ml  TTP, Ibbenbüren 
Sterile Workbench,      NuAire Biological Safety Cabinets, 
Sterile Workbench, Model Gelaire BSB 4A  Gruppo Flow s.p.a. OPERA, Italy 
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2.1.2 Chemicals and reagents 
Biocoll (Ficoll®)      Biochrom, Berlin 
DMSO (Dimethylsulfoxid)     Merck KGaA, Darmstadt 
Dulbecco’s PBS (1x)      PAA, Cölbe 
FCS (fetal calf serum) Gold     PAA, Cölbe 
Fixation Medium – Medium A    Invitrogen, Karlsruhe 
Hank’s BSS (1x)      PAA, Cölbe 
HEPES Buffer Solution (1M)    PAA, Cölbe 
L-Glutamin 200mM (100x)     PAA, Cölbe 
Penicillin/ Streptomycin (100x)    PAA, Cölbe 
Permeabilization Medium – Medium B   Invitrogen, Karlsruhe 
PHA (Phytohaemagglutinin)     Sigma Aldrich, Taufkirchen 
RPMI1640, without L-Glutamin    PAA, Cölbe 
Tween-Solution     Sigma Aldrich, Taufkirchen 
 
2.1.3 Solutions  
Hanks: 
Hank’s Balanced Salt Solution (HBSS) containing no glutamine was modified by adding 5 ml 
L-Glutamin, 5 ml Penicillin/Streptomycin and 5 ml HEPES buffer. 
 
R10: 
RPMI1640 medium containing no glutamine and was modified by adding 5 ml L-Glutamin, 
5 ml Penicillin/Streptomycin, 5 ml HEPES buffer and 50 ml FCS (inactivated via heat at 56°C 
for 1 hr). 
 
R20: 
RPMI1640 medium containing no glutamine was modified by adding 5 ml L-Glutamin, 
5 ml Penicillin/Streptomycin, 5 ml HEPES buffer and 100 ml FCS (inactivated via heat at 56°C 
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2.1.4 Antibodies  
Table 1: Antibodies used to detect myeloid cell surface antigen. 
Antigen Fluorochrome Species Supplier per 106 cells 
CD11b FITC Mouse BioLegend, USA 3 μl 
CD14 APC Mouse BioLegend, USA 3 μl 
CD15 PerCP Mouse BioLegend, USA 3 μl 
CD66 PE Mouse BioLegend, USA 3 μl 
CD33 PE Mouse BioLegend, USA 3 μl 
HLA-DR HLA-DR-PerCP Mouse BioLegend, USA 1 μl 
HLA-DR PerCP isotype 
control 
Mouse BioLegend, USA 2 μl 
 
2.1.5 Peptides 
Synthetic peptides corresponding to the HIV proteins Gag and Nef were used for screening 
(Gag: HIV-1 SF-2, Nef: HIV-1 Bru, NIBSC, England) with a purity of ≥ 70%. (55) 
 
Table 2: Peptides corresponding to HIV protein Gag. 
Peptide Sequence Peptide Sequence 
1 MGARASVLSGGELDK 2 GELDKWEKIRLRPGG 
3 LRPGGKKKYKLKHIV 4 LKHIVWASRELERFA 
5 LERFAVNPGLLETSE 6 LETSEGCRQILGQLQ 
7 LGQLQPSLQTGSEEL 8 GSEELRSLYNTVATL 
9 TVATLYCVHQRIDVK 10 RIDVKDTKEALEKIE 
11 LEKIEEEQNKSKKKA 12 SKKKAQQAAAAAGTG 
13 AAGTGNSSQVSQNY 14 PIVQNLQGQMVHQAIISPRTL 
15 VHQAISPRTLNAWVKVVEEK 16 NAWVKVVEEKAFSPEVIPMF 
17 AFSPEVIPMFSALSEGATPQ 18 SALSEGATPQDLNTMLNTVG 
19 DLNTMLNTVGGHQAAMQMLK 20 GHQAAMQMLKETINEEAAEW 
21 ETINEEAAEWDRVHPVHAGP 22 DRVHPVHAGPIAPGQMREPR 
23 IAPGQMREPRGSDIAGTTST 24 GSDIAGTTSTLQEQIGWMTN 
25 LQEQIGWMTNNPPIPVGEIY 26 NPPIPVGEIYKRWIILGLNK 
27 KRWIILGLNKIVRMYSPTSI 28 IVRMYSPTSILDIRQGPKEP 
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Peptide Sequence Peptide Sequence 
29 LDIRQGPKEPFRDYVDRFYK 30 FRDYVDRFYKTLRAEQASQD 
31 TLRAEQASQDVKNWMTETLL 32 VKNWMTETLLVQNANPDCKT 
33 VQNANPDCKTILKALGPAAT 34 ILKALGPAATLEEMMTACQG 
35 LEEMMTACQGVGGPGHKARV 36 AEAMSQVTNPANIMM 
37 ANIMMQRGNFRNQRK 38 RNQRKTVKCFNCGKE 
39 NCGKEGHIAKNCRAP 40 NCRAPRKKGCWRCGR 
41 WRCGREGHQMKDCTE 42 KDCTERQANFLGKIW 
43 LGKIWPSYKGRPGNF 44 RPGNFLQSRPEPTAPPE 
45 EPTAPPEESFRFGEE 46 RFGEEKTTPPQKQEPI 
47 QKQEPIDKELYPLTS 48 YPLTSLRSLFGNDPSSQ 
 
Peptide Position Sequence 
SL9 Gag77-85 SLYNTVATL 
 
 
Table 3: Peptides corresponding to HIV protein Nef. 
Peptide Sequence Peptide Sequence 
49 GGKWSKSSVVGWPTVRERMR 50 GGKWSKSSVVGWPTVRERMR 
51 RAEPAADGVGAASRDLEKHG 52 AASRDLEKHGAITSSNTAAT 
53 AITSSNTAATNAACAWLEAQ 54 NAACAWLEAQEEEEVGFPVT 
55 EEEEVGFPVTPQVPLRPMTY 56 PQVPLRPMTYKAAVDLSHFL 
57 KAAVDLSHFLKEKGGLEGLI 58 KEKGGLEGLIHSQRRQDILD 
59 HSQRRQDILDLWIYHTQGYF 60 LWIYHTQGYFPDWQNYTPGP 
61 PDWQNYTPGPGVRYPLTFGW 62 GVRYPLTFGWCYKLVPVEPD 
63 CYKLVPVEPDKVEEANKGEN 64 KVEEANKGENTSLLHPVSLH 
65 TSLLHPVSLHGMDDPEREVL 66 GMDDPEREVLEWRFDSRLAF 
67 EWRFDSRLAFHHVARELHPE 68 HHVARELHPEYFKNC 
 
 




CellQuest       BD, Heidelberg 
EliSpot Reader Version 5.0     AID, Strassberg 
FACSDiva Version 6.0     BD, Heidelberg 
FlowJo Version 7.2.1     Tree Star Inc., Ashland, USA 
GraphPad Prism Version 5.0    GraphPad Software, La Jolla, USA 
 
2.2 Methods  
2.2.1 Study Subjects 
43 individuals participated in the study after signing informed consent: 19 patients (PHI, n  = 
8, CHI, n = 11) within the scope of an amendment of the New Era study (EudraCT Number 
2008-002070-35, approved by the Bayerische Landesärztekammer (BLAEK) and the German 
federal institute for drugs and medical devices (BfARM)) and 23 individuals within 4 control 
groups (study approval by the Institutional Review Board of the Ludwig-Maximilians-
Universität, Munich, Germany). (55) 
 
The control groups were defined as follows:  
• PR (Progressor) were defined as untreated patients during chronic HIV infection at the 
time of blood draw. We considered 6 PR with a CD4 cell count below 400 cells/µl and 
viral load (VL) above 10000 copies/ml 
• CO (Controller) were defined as patients who were able to control HIV infection 
spontaneously in the absence of cART. We considered 7 individuals with a CD4 cell 
count above 500/µl and a VL below 2000 copies/ml. This also included 3 Elite 
Controllers who were defined as patients with a viral load below 50 copies/ml. 
• 3ART were defined as patients who had received a conventional cART for at least 48 
months. We considered 5 patients for the 3 ART control group with any CD4 cell count 
but an undetectable VL below 40 copies/ml. 
• HC (Healthy controls) were 5 individuals who were not infected with HIV.  
A summary of study participants and their clinical characteristics, CD4 cell counts and VL, can 
be found in Table 4 below.  
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Table 4: Study subjects and their clinical characteristics. 
Clinical characteristics of study participants at the time of blood draw are shown below. Clinical data is shown in median values of each group as well as its range. CD4 cell count 
is reported in cells/µl and viral load (VL) is reported in copies/ml. The detection limit for VL was 40 copies/ml in this study. Age is given in years and treatment length is given in 
months. Treatment in PHI and CHI refers to the length on intake of the intensified treatment. For CHI the length of conventional treatment (cART) prior to the intensified regimen 
is also shown. Treatment for 3ART refers to a conventional antiretroviral treatment (cART). Not applicable is abbreviated as ‘n.a.’, female as ‘f’ and male as ‘m’. 












Gender 2m/3f 7m/1f 9m/2f 5m/0f 5m/2f 5m/1f 
 Age  48.6 47.5 49.5 45.8 45.3 38.6 
Range 42 - 55 42 - 56 36 - 62 30 – 70 30 - 66 20 - 56 
CD4 cell count n.a. 790.5 662 591 578 81 
Range n.a. 557 - 1342 551 - 1133 487 - 687 467 - 1442 49 - 205 
VL n.a. <40 <40 <40 51 177453 
Range n.a. n.a. n.a. n.a. <40 - 702 2100 - 540539 
Treatment length n.a. 72.5 65 
cART: 77.6 
94 n.a. n.a. 
Range n.a. 68 - 77 55 - 71 
cART: 49 - 126 
51 - 207 n.a. n.a. 
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2.2.2 Procedures  
A schematic outline of the sequence of procedures that was carried out in this study can be seen 
in Figure 3. The individual steps are described in detail in the following sections.  
 
Figure 3 briefly outlines the sequence of procedures carried out in this study. After signing the informed consent, 
6-12 large EDTA tubes of blood were drawn from the patient. PBMC were isolated from the whole blood within 
a time frame of 4 hrs to be studied by FACS on the same day. The Elispot technique did not need to be carried 
out on the same day so that all extracted cells were first cryo-conserved and thawing could be performed on 
another day independent of the time of blood collection. 
 
 
2.2.3 Blood sample collection procedure  
Peripheral venipuncture was carried out to obtain 6 to 12 EDTA tubes, each containing a 
volume of 30 to 50 ml of whole blood. After obtaining the patient’s whole blood, the viral 
load was measured by the means of Real-time-polymerase chain reaction (RT-PCR) whereas 
the CD4 cell count was measured by flow cytometry (BD Tritest).  
Blood draw 
 
Figure 3: Outline of the sequence of procedures. 
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The blood draw was performed by the nurses whereas the laboratory methods were carried 
out by the medical technical assistants.  Following the collection of clinical data relevant in 
monitoring HIV progression, isolation of the cell population of interest was performed.  
2.2.4 PBMC Isolation from whole blood 
Cell population of interest are lymphocytes which belong to the group of peripheral blood 
mononuclear cells (PBMC). They were separated from fresh whole blood via density gradient 
centrifugation using Ficoll. The Ficoll media is a neutral hydrophilic polysaccharide with a 
density of 1.077 g/ml. The blood sample was carefully layered with the Ficoll media in order 
to counteract mixing. Individual cell populations of blood were centrifuged at a high speed of 
1500 U/min for 30 min at 18 to 20°C. The centrifuge brake was turned off during centrifugation 
resulting in a separation of different cells divided into three layers: the upper layer contains 
light cells (thrombocytes) whereas lymphocytes as well as monocytes can be found in the 
central layer just above the Ficoll media. Red blood cells and granulocytes gather at the bottom 
of the centrifuge tube (see the red circle in Figure 4).  
 
Figure 4 shows the different layers of cells which form after Ficoll media has been added to a blood sample with 
the aim of isolating mononuclear cells (red circle). (56) 
 
 
Lymphocytes and monocytes were carefully obtained with a sterile pipette and transferred to a 
sterile centrifuge tube of 50 ml. The cell suspension was washed three times (10 min, at room 
temperature, 1500 U/min). Hanks medium was used for the first two washings whereas R10 
was used for the third wash. The supernatant was removed and the remaining cell pellet 
containing mononuclear cell was resuspended in 10 ml of R10. 
 
Figure 4: PBMC isolation from whole blood. 
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2.2.5 Cell counting 
Isolated PBMC were counted with an electric field multi-channel count system called CASY®. 
50 μl of the previously obtained cell pellet were suspended in CASY®Ton, an isotonic salt 
solution with a physiological pH. To analyse viability of counted cells, 10 μl of cells were mixed 
with an equal amount of trypan blue and inserted into the KOVA® cell chamber system. The 
used dye only stains non-viable cells whereas viable cells are spared. Thus, determining the 
count of viable cells was based on an exclusion method. The ratio of viable vs. non-viable cells 
from the cell chamber multiplied by the result of CASY® cell counter led to the number of 
viable cells of the cell pellet. 
2.2.6 Cryo-conservation of extracted cells 
Cryo-conservation of cells enables the researcher to preserve cells for a significant amount of 
time in liquid nitrogen. The cell suspension was first centrifuged at 1500 U/min for 10 min at 
4°C. Supernatant was removed and the remaining cell pellet was resuspended in a 1 ml solution 
consisting of two cryo-protective agents composed of 90% pure FCS and 10% DMSO. Then 
an additional amount of the cryo-protective solution was quickly added and the total volume 
was equally transferred into cryovials. Each cryovial received a total volume of 1.8 ml with a 
cell count of 106 cells/ml. The cryotubes were immediately transported to the Thermo Scientific 
Mr. Frosty freezing container filled with isopropanol. Frozen cells were stored overnight at -
80°C. On the consecutive day they were transferred to a liquid nitrogen tank (-196°C) for long-
term storage. 
2.2.7 Thawing of frozen cells 
Frozen cells which were stored in a liquid nitrogen tank were quickly thawed in a heated bath 
and transferred into cold centrifuge tubes to reduce cell damage. After 10 ml of R10 had been 
added, two washings of the cell suspension were carried out for 10 min with a speed of 1500 
U/min. The first washing was performed at 4°C whereas the second was performed at room 
temperature. Following each centrifugation step, supernatant was removed and cells were 
resuspended in 2 ml of R10. 10 µl of the cell suspension was used to count the cells and 
determine their viability as outlined in 2.2.5. Afterwards cells were transferred into cell culture 
flasks with a volume of 25 cm
3
. Each flask contained 1.5 x 10
6
 cells per 1 ml of R10. For 
optimal cell storage, they were kept in an incubator at 37°C and 5% CO2 overnight. 
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2.2.8 Interferon- Elispot 
2.2.8.1 Procedure of the Elispot assay 
The enzyme-linked immunospot assay is a sensitive and accurate method that identifies cell-
based immune responses by measuring secretory products of immune cells in response to a 
certain stimulus (see Figure 5).  
Figure 5 briefly outlines the principles of the Elispot assay which lasts 3 days and employs an antibody ‘sandwich’ 
technique. The first day focuses on coating the polyvinylidene diflouride (PVDF) microtiter plate with a primary 
antibody specific to the analyte of interest. Cells that are capable of secreting this analyte are given into the wells 
of the 96-well plate and are incubated overnight to allow binding of the secreted analyte and antibody. The second 
day is used to wash off any cells not bound to the primary antibody. This is followed by the addition of a secondary 
antibody specific to the analyte of interest. It is also biotinylated to allow binding to the Alkaline phosphatase 
conjugated streptavidin on the following day. A second incubation period is carried out. On the third day, a 
substrate solution (BCIP/NBT) is added so that streptavidin catalyzes a reaction that leads to the precipitation of 















Figure 5: Principle of the Elispot assay. 
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In this study the secretion of interferon-gamma by CD8 T lymphocytes was measured. At first, 
a 96-well PVDF-membrane microtiter plate was coated with 100 μl of a solution made up of 
11 μl of the primary antibody, mAb 1-D1K (1 mg/ml), and 11 ml of sterile PBS. The 96-well 
microtiter plate were kept in the fridge overnight at 4°C.  
On the consecutive day, each well of the microtiter plate was repeatedly washed with 200 μl of 
PBS and 1% of FCS for 6 times. After the final wash, 50 μl of R10 was given to each of the 96 
wells. Then, 10 μl of a certain peptide (200 µg/ml) depending on the position of the well on the 
plate was added (see 2.1.5). Finally, an equal amount of PBMC cell suspension (100000 cells 
per well) were given into each well. Negative controls contained PBMC and R10 only whereas 
positive controls contained PBMC with either PHA or FEC, a mixture of as optimally defined 
CD8 T cell epitopes of Influenza virus, Epstein-Barr-Virus and Cytomegalovirus. Both types 
of controls were run as triplicates. The plate was placed in the incubator overnight at 37°C and 
5% CO2 to allow sufficient time for cytokine production.  
On the third day of the procedure, the plate was washed 6 times with PBS only. 5.5 µl of the 
secondary antibody, mAb 7B6-1-biotin, was resuspended in 11 ml of PBS and the solution was 
used to coat the 96-well microtiter plate, each well receiving 100 µl. The plate was placed in 
the dark for an incubation period of 1 hr and was once again washed 6 times with PBS. 
Following the washings, streptavidin which is a strong binding agent to the previously added 
biotin was applied. For this purpose, 5.5 µl of streptavidin had been suspended in 11 ml of 
sterile PBS and a 100 µl had been given into each well. The plate was again kept in the dark for 
an incubation time of 45 min. Before applying a colouring solution, the plate underwent a series 
of 6 washings using PBS. The colouring solution contained the following reagents: 12 ml of 
distilled water, 500 µl of Tris-HCl-Buffer and two colouring reagents, AP colour reagents A 
and B, of 125 µl each. Due to colour development, blue spots became clearly visible in positive 
wells. Then, each well of the microtiter plate was sterilised with 200 µl of 0.05% Tween 
solution which had previously been suspended in PBS. Following a 10 min rest, plates were 
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2.2.8.2 Analysis of the Elispot assay 
Elispot plates were read out by an automated Elispot Reader. The number of spot-forming cells 
(SFC) per well was counted by the reading device and calculated per 106 PBMCs. In case of 
minor colour development in the negative controls (≤ 5 SFC/106 PBMCs), spots were counted 
individually for each well and were considered positive when at least 50 SFC/106 PBMCs was 
reached. If the median in the negative controls exceeded 5 SFC/well, a well was only considered 
positive if it exceeded the total number of SFC/106 PBMCs in the negative controls at least 3 
times. Since the Elispot reader reaches its limit to discriminate all the spots formed at 2000 
SFC/106 PBMCs, this was chosen as the upper cut-off limit. To determine the number of CD8 
T cell responses, the following formula was used:   
 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝𝑜𝑡𝑓𝑜𝑟𝑚𝑖𝑛𝑔 𝑐𝑒𝑙𝑙𝑠 −  𝑚𝑒𝑎𝑛 𝑜𝑓 𝑡𝑟𝑖𝑝𝑙𝑖𝑐𝑎𝑡𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑣𝑎𝑙𝑢𝑒𝑠   
         = 𝑎𝑐𝑡𝑢𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐶𝐷8 𝑇 𝑐𝑒𝑙𝑙 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠 
 
Since neighbouring synthetic peptides overlapped each other for 5-10 amino acids at their ends 
(Table 5), it is possible to overestimate the breadth and magnitude of CD8 T cell responses. To 
avoid overestimation, we referred to the method used in Addo et al from 2003: In terms of 
breadth, responses to neighbouring peptides were only counted once. In terms of magnitude, 
the higher response according to the number of SFC/106 PBMCs was chosen. (53) 
 
Table 5: Overlapping synthetic peptides in Gag p17 and Gag p24. 
In order to demonstrate the overlap of sequences in the synthetic peptides used in this study, two HIV-specific 
sequences from Gag p 17 and Gag p24 were chosen as examples. The sequences are found at the beginning and 







No. of overlapping 
amino acids 
p17 1 MGARASVLSGGELDK 5 
p17 2 GELDKWEKIRLRPGG 
p24 26 NPPIPVGEIYKRWIILGLNK 10 





Materials and Methods 
33 
 
2.2.9 Flow cytometric analysis 
Flow cytometry is a laser-based technology which assesses physical as well as chemical 
properties of thousands of particles. It allows rapid separation of cell types from a 
heterogeneous mixture of different cells. In this study, expression of phenotypic markers of two 
cell populations of interest, PMN and M-MDSC, was detected with the help of several 
fluorescent antibodies (see Table 1). Figure 6 briefly outlines the principle of fluorescence-
activated cell sorting (FACS).  
Figure 6: Principle of FACS. 
Figure 6 illustrates the principle of FACS with a flow sorter. Cells have been stained with a fluorescent dye 
specific to a certain extracellular marker. The cell flow allows the analysis of one cell at a time. The sheat fluid 
within the cell flow carries a cell ‘single file’ through a lightbeam with multiple lasers of different wavelengths 
and fluorescence detectors. The detector converts forward and side scattered light as well as fluorescence 
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2.2.9.1 FACS procedure 
For the detection of MDSCs in previously isolated PBMCs, it was crucial to use fresh PBMCs. 
According to Grützner et al, it is important to study particularly M-MDSCs within 4 hrs of 
blood draw to avoid a significant loss of these cells. This finding does not apply to PMN-
MDSCs to the same extent. However, a significant delay in FACS analysis will also limit proper 
analysis of FACS data. (28)  
Fresh PBMCs with a concentration of 1 x 106 cells/ml were washed in a solution of 2 ml of 
PBS and 20 µl of FCS. This was followed by a centrifugation of 10 min at 4°C with a speed of 
1500 rpm. Supernatant was removed and extracellular staining was carried out in the dark. First, 
50 µl of PBS were added to resuspend the cell pellet. Then, antibodies were added and 
immediately stored in the fridge for a 30 min incubation period. Afterwards they were again 
resuspended with PBS and centrifuged at the previously used setting. Following the removal of 
supernatant, 100 µl of a fixation reagent, Fix Perm Solution A, was added and left in the dark 
for incubation for 15 min at room temperature. Another wash with 2 ml of PBS and a final 
centrifugation were carried out. At last, stained cells were resuspended in 200 µl of PBS. They 
were analysed on FACSCalibur and 100000 cells were counted for each sample. The obtained 
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2.2.9.2 Gating strategies  
Gating strategies were according to Vollbrecht et al and Rieber et al for PMN-MDSCs. (31; 58) 
To identify M-MDSCs, gating strategies were used according to Dumitru et al. (59) A detailed 
description of the strategy can be found in Figure 7.  
Figure 7: Representative dot blots and gating strategy for PMN-MDSCs. 
Figure 7 describes the gating strategy for determining the frequency of PMN-MDSC within a heterogeneous cell 
mixtures of fresh PBMCs. Since PMN-MDSCs are defined as CD11b+/CD14- and CD66b+/CD15+, the following 
strategy was applied to identify cells with these characteristics. First, the monocytic fraction in FSC and SSC is 
found and gated (green gate in the first panel). MDSCs are mainly found in the smaller fraction located just above 
the monocytic ‘bulk’. The green squared gate in the second panel then includes a CD11b+/CD14-  cell population. 
In the third panel, those cells are further gated into CD66b+/CD15+ (green gate).  
 
Figure 8: Representative dot blot and gating strategy for M-MDSCs. 
Figure 8 describes the gating strategy used to identify M-MDSCs from a fresh PBMC mixture. They are defined 
as CD14+/CD11b+/HLA-DR- and CD33+. The first panel serves to identify the fraction of lymphocytes and 
monocytes in FSC and SSC which is located in the green squared gate. Once this fraction is identified, the second 
panel uses a PerCP isotpye control to identify the HLA-DR negative population. In the third panel, cells that are 
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2.2.10  Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5.0. Obtained data was found 
to be non-parametric and was therefore analysed by non-parametric tests.  Comparisons done 
within one study group were analysed using the Mann-Whitney-U-test. Regarding the 
comparison of different groups of HIV patients, the type of analysis was chosen according to 
the number of groups considered. When comparing two groups, Mann-Whitney-U-test was 
again applied whereas Kruskal-Wallis testing was performed when more than two groups were 
included in the comparison. A p-value of < 0.05 was considered to be statistically significant. 
For multiple comparisons, Bonferroni correction was applied when p was significant in 
Kruskal-Wallis testing. p-value significance changed to < 0.0167 for 4 groups and < 0.0175 for 





3.1 Low frequencies of PMN-MDSC amongst NE, 3ART and CO  
Frequencies of PMN-MDSC of New Era patients (NE) were compared to other groups of HIV 
patients of this study as well as to healthy control. NE patients showed comparably low 
frequencies of PMN-MDSC to 3ART who had also received treatment for HIV. Furthermore, 
both groups receiving HIV treatment, NE and 3ART, showed similarly low frequencies of 
PMN-MDSC when compared to HC. Furthermore, CO patients also showed comparably low 
levels of PMN-MDSC with respect to HC and HIV patients with treatment, NE and 3ART. The 
only group of patients showing a significantly higher level of PMN-MDSC to NE patients was 
the PR group who had not received any treatment for their HIV infection (p = 0.0008). 
These results suggest that despite differing drug regimens, HIV treatment must have had a 
similar impact on NE and 3ART regarding PMN-MDSC frequencies. The significant difference 
between the NE and PR patients further underlines the effect of treatment on PMN-MDSC 
frequency in HIV patients. It is also noteworthy that CO patients’ ability to naturally control 
HIV infection appeared to lead to similarly low frequencies of PMN-MDSC as seen in HC. 
 
 








3.2 No difference between frequencies of PMN-MDSC in NE subgroups  
When analysing NE subgroups individually, frequencies of PMN-MDSC in both, PHI and CHI, 
were low. Comparison to the control groups of this study showed similar results to the analysis 
which considered NE patients collectively (Figure 10).  
Thus, both subgroups showed similar levels of PMN-MDSC frequency as seen in HC, 3ART 
and CO whereas significantly lower frequencies were observed when compared to PR (p = 
0.0047; p = 0.0019). In a comparison between PHI and CHI, no significant difference between 
their PMN-MDSC frequencies was seen (p = 0.999). This suggests that the starting point of the 
5-drug regimen did not have a major impact on frequencies of PMN-MDSC in NE patients. 





Figure 10: Frequencies of PMN-MDSC in NE subgroups. A Comparison between PHI and control groups 
(Kruskal-Wallis test). B Comparison between CHI and control groups (Kruskal-Wallis test). C Comparison 
between PHI and CHI (Mann-Whitney-U-Test). 




3.3 Frequencies of M-MDSC in NE patients are significantly higher than in 
healthy controls 
In contrast to PMN-MDSC frequencies, NE patients showed a significantly higher level of   M-
MDSC frequencies when compared to HC (p = 0.0014). No significant difference between the 
HIV groups, NE and 3ART, receiving HIV treatment could be detected. Although not 
statistically significant, M-MDSC frequencies of HIV patients were higher when compared to 
HC, even in HIV patients receiving continuous treatment.  
Moreover, NE patients did not show a significant difference of their M-MDSC frequencies 
when compared to the HIV patients, CO and PR, who did not receive any treatment (p = 0.91; 
p = 0.78). However, the difference between NE patients and PR patients would probably 
become statistically significant if the groups were bigger. 
The results suggest that HIV treatment had a similar effect on M-MDSC frequencies 
independent from the type of drug regimen applied. Although not statistically significant, PR 
patients showed considerably higher M-MDSC frequencies when compared to the other groups 
in this study. This underlines the effect of HIV treatment on those cells. Nonetheless, 
frequencies of M-MDSC in any HIV group did not reach the level observed in HC. Thus, HIV 
treatment does not appear to have the same effect on M-MDSC frequencies as it does on PMN-
frequencies.  
 
Figure 11: Frequencies of M-MDSC in NE patients and control groups (Mann-Whitney-U-test). 
 
 




3.4 M-MDSC frequencies differ between NE subgroups 
In contrast to PMN-MDSC frequencies, NE subgroups showed significant differences in their 
M-MDSC frequencies. PHI showed a trend towards higher levels of M-MDSC frequencies 
when compared to HC (p = 0.0186) whereas this trend was not observed in CHI (p = 0.038). 
Besides, CHI also appeared to have significantly lower M-MDSC frequencies than 3ART who 
had also received HIV treatment (p = 0.0009). In fact, their level of M-MDSC frequency was 
comparable to the level seen in HC. Furthermore, CHI showed significantly lower M-MDSC 
frequencies than CO who are able to naturally control HIV infection and did not receive any 
treatment (p = 0.0114).  
Comparing NE subgroups, no significant difference could be detected (p = 0.21). Nonetheless, 
Figure 12 C illustrates that M-MDSC frequencies of PHI were generally higher and showed a 
wider distribution than CHI. 
Although there was no significant difference observed in the comparison of M-MDSC 
frequencies between the NE subgroups, the results suggest that PHI drive the significantly 
higher frequencies of M-MDSC in NE patients when compared to HC (Figure 12). Despite their 
late onset of HIV treatment, CHI had been treated with a cART regimen for at least 36 months 
prior to the start of the 5-drug regimen. Thus, they were expected to be in an adequate 
immunological status at the start of the 5-drug regimen which might not have been the case for 










Figure 12: Frequencies of M-MDSC in NE subgroups. A Comparison between PHI and control groups 
(Kruskal-Wallis test). B Comparison between CHI and control groups (Kruskal-Wallis test). C Comparison 
between PHI and CHI (Mann-Whitney-U-test). 
  
p = 0.0186 
p = 0.0114 




3.5 CHI tend to have broader HIV-specific immune responses than PHI 
The HIV-specific CD8 T cell response was examined in the four groups of HIV patients of this 
study and breadth and magnitude were analysed. Despite an intensified HIV treatment, the 
breadth of HIV-specific CD8 T cell responses did not significantly differ between the NE cohort 
and the other groups of HIV patients (p = 0.3458). 
Comparing the two subgroups within the NE cohort with regard to their individual level of 
breadth, it is worth noticing that CHI tended to show a broader CD8 T cell response specific to 
HIV than PHI (p = 0.062). Moreover, the mere number of responses towards Gag and Nef 
varied considerably between patients of the CHI subset (range: 0 to 16). Consequently, CHI 
appeared to be the dominant subset of patients within the NE cohort that drives the level of 
breadth observed for immune responses in NE patients.  
(A) (B)  
  
Figure 13: Breadth of CD8 T cell responses towards Gag and Nef. A Comparison between NE and control 









3.6 NE patients have slightly stronger immune responses than 3ART 
The HIV groups of this study were analysed according to their individual levels of magnitude 
of the CD8 T cell response. In contrast to the results obtained for the level of breadth, the NE 
cohort showed slightly stronger CD8 T cell responses to HIV proteins when compared to the 
3ART patients (p = 0.083). When considering the level of magnitude for the two subsets of NE 
patients, no significant difference between PHI and CHI was detected (p = 0.2185). Thus, CHI 
tended to have a broader response of HIV-specific CD8 T cells than PHI, but their magnitude 
of immune responses was comparable. 
(A) (B) 
  
Figure 14: Magnitude of CD8 T cell responses towards Gag and Nef. A Comparison between NE and control 
groups (Kruskal-Wallis test). B Comparison between PHI and CHI (Mann-Whitney-U-test). 
 
3.7 CHI patients target all studied HIV-proteins – similar to CO patients 
In order to investigate CD8 T cell responses which are specific to HIV, 4 of the most commonly 
recognized HIV-1 proteins, namely Gag p17, Gag p24, Gag p15 and Nef were assessed in the 
experiments. The average number of CD8 T cell responses was determined for the viral proteins 
investigated within every group of HIV patients of this study. 
As shown above, CHI patients had generally broader responses to Gag and Nef, especially when 
compared to 3ART (p = 0.0286). Interestingly, CD8 T cells in CHI targeted all HIV proteins 
studied when compared to PHI patients (p = 0.0857). The CO patients who did not receive any 
treatment over their course of infection showed broad CD8 T cell responses for all 4 proteins. 




In this respect, CHI patients were similar to CO patients. 3ART patients who received a 
standard antiretroviral therapy showed generally narrow responses of CD8 T cells to all 4 HIV-
1 proteins. This represents an interesting finding, also in comparison to the 3ART patients as 
duration of HIV treatment was similar for both groups. It emphasizes that this subgroup of the 
NE cohort was a special group of patients selected. 
The PR group which had already reached an advanced stage of HIV infection also showed broad 
responses in Nef and Gag p24 whereas responses to Gag p17 and Gag p15 were relatively 
narrow. The broadest responses in NE patients were observed for Nef followed by Gag p24 as 
earlier studies have also identified Nef as a highly immunogenic protein. Correspondingly, 
these two proteins were also found to have the broadest responses among all other HIV study 
groups. 
 
Figure 15: Breadth of CD8 T cell responses to Gag and Nef (Kruskal-Wallis test). 
 
3.8 PHI and CHI patients show similar levels of magnitude within the 
different HIV proteins studied  
Whilst CHI showed broader HIV-specific immune responses than PHI, no major difference in 
magnitude between PHI and CHI was seen (p = 0.2927) (see Figure 14 B). Immune responses 
in 3ART appeared to be rather similar to the NE cohort except for Gag p17 and Nef. Similarly 
to the results regarding the levels of breadth, Nef also triggered strong responses in most of the 




CO patients had the highest results in magnitude amongst all study groups. PR patients only 
showed strong responses to Nef but considerably low levels of magnitude for the other 3 HIV 
proteins investigated.  
In summary, Nef did not only elicit the most responses but also the strongest. In contrast to 
breadth, magnitude in the NE subgroups, PHI and CHI, was comparable and did not differ to 
3ART patients. However, CO patients who had no antiretroviral therapy showed stronger 
responses. This suggests that HIV treatment has a reducing effect on the magnitude but differing 
drug regimens do not lead to significantly different levels of magnitude. Most likely the 
important variable is viral load – which is reduced in all regimens. (55) Moreover, the low level 
of magnitude observed in the PR patients again underlines the potential effect of immune 
exhaustion on effector cells.  
 
Figure 16: Magnitude of CD8 T cell responses to Gag and Nef (Kruskal-Wallis test). 
 
3.9 No correlation between frequencies of immune suppressive cells and the 
level of Gag/Nef-specific immune responses in the NE cohort 
Immune suppressive cells are known for their inhibitory effect on CD8 T cell responses. 
Therefore, this analysis further focused on the correlation between MDSCs and HIV-specific 
CD8 T cells in the NE patients. However, there were no correlations found between the different 
subsets of MDSCs including PMN- and M-MDSC and breadth or magnitude of HIV-specific 
CD8 T cell responses, respectively (see Figure 17). This implies that both subsets of immune 




(A) (B)  
  
(C)  (D) 
  
Figure 17: Frequencies of MDSC plotted against HIV-specific immune responses of the NE cohort. (Spearman 
rank test). A Correlation between breadth and PMN-MDSC frequency. B Correlation between magnitude and 
PMN-MDSC frequency. C Correlation between breadth and M-MDSC frequency. D Correlation between 
magnitude and M-MDSC frequency.  
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This study investigated the effect of an intensified HIV treatment on MDSCs and the breadth 
and magnitude of CD8 T cell responses in correlation to these in the NE cohort and other groups 
of HIV-infected individuals as controls. Of particular interest was the impact of different 
starting points of the intensified treatment on the two NE subsets. As the NE study aimed to 
eradicate HIV-1 on a long term, these findings were acquired previously to a possible 
interruption of HIV treatment. The results of this study showed that antiretroviral treatment 
leads to a reduced level of MDSC frequencies in HIV patients whereas the absence of treatment 
resulted in higher frequencies as has been shown before. This particularly applied to the levels 
of PMN-MDSC in treated individuals since this subset of cells showed almost normal levels as 
seen in HC. There was no advantage for NE patients under an intensified drug regimen in 
comparison to the HIV patients with a conventional drug regimen in terms of MDSCs and 
immune responses. Interestingly, NE patients showed surprisingly broad immune responses. 
Furthermore, the early start of therapy in the PHI subgroup did not result in lower MDSC 
frequencies when compared to the CHI patients. Finally, there were no correlations identified 
between MDSC frequencies and breadth or magnitude of CD8 T cell responses, respectively. 
4.1 Myeloid-derived suppressor cells 
4.1.1 Antiretroviral treatment reduces PMN-MDSCs close to normal levels 
Within the NE cohort and 3ART patients, PMN-MDSC levels were low and close to normal 
when compared to the healthy individuals of this study. These findings are consistent with other 
studies which show the decline of MDSCs after initiation of HIV treatment implying that HIV 
treatment is effective in reducing MDSC levels. (31) In our analysis, we were not able to find 
differences between a conventional ART consisting of three drugs and the intensified treatment 
regimen used in the New Era study. Nevertheless, a few HIV patients under treatment showed 
higher PMN-MDSC levels than what one would expect to find. Thus, antiretroviral treatment 
does not necessarily lead to normal levels in every HIV patient and apparently also applies to 
the intensified HIV treatment of this study. As a limitation of this study, there are no data 
available for MDSCs prior to HIV infection and thus it is not possible to compare individual 
levels of MDSC before and after infection for the HIV patients. However, the kinetics of MDSC 
frequencies before and during infection were also investigated in the longitudinal study by 
Dross et al. Healthy rhesus macaques were infected with SIV and several blood draws were 




In week 6 of the infection, the macaques started to receive an antiretroviral treatment which is 
comparable to a standard drug regimen in humans. Results showed low MDSC frequencies in 
the macaques prior to infection whereas the acute stage of the infection led to a slight yet 
significant elevation. Despite effective treatment starting at week 6 this elevation remained over 
the full course of treatment which lasted 31 weeks. (40) 
4.1.2 Antiretroviral therapy has a greater effect on PMN-MDSCs than on M-MDSCs  
M-MDSC levels are generally higher than PMN-MDSC levels within the NE cohort as well as 
the 3ART patients and thus do rarely reach normal levels. Therefore, it can be concluded that 
M-MDSC levels appear to be higher no matter which treatment regimen was chosen. Overall, 
it suggests that the intensified treatment had a lesser effect on the reduction of M-MDSC 
frequencies than it had on PMN-MDSC levels.  
4.1.3 Early intensified treatment does not lead to an observable advantage  
Surprisingly, no statistical differences were detected between PHI and CHI in regard to MDSC 
frequencies. Although the highest percentages regarding MDSCs were found in CHI patients, 
it is not possible to deduce a beneficial effect for the patients with an early treatment start from 
this data, at least not in terms of the investigated suppressive cells of this thesis. However, it 
needs to be taken into account that the number of HIV patients in every group was relatively 
small in order to reveal statistical significances.  
4.1.4 CHI patients represent a special group within the NE cohort 
A difference in M-MDSC levels can be found, though not statistically relevant, when 
considering the two subgroups within the NE cohort individually. Interestingly, patients who 
had started their intake of the 5-drug regimen during their acute phase of infection tended to 
have M-MDSC frequencies which were higher than in healthy controls. In contrast, M-MDSC 
frequencies of CHI were comparable to HC. This underlines that CHI represent a special group 
of HIV patients as they had to fulfil certain criteria to be included in the NE study in the first 
place. One of those had been a continuous HIV treatment regimen with a protease inhibitor for 
at least 36 months prior to the start of the intensified treatment. Another one was the requirement 
that patients of the CHI groups were not allowed to have had a viral blip in the years before 





4.1.5 The lack of antiretroviral treatment correlates with high frequencies of MDSC 
In untreated HIV progressors, levels of MDSC were considerably elevated when compared to 
uninfected individuals for both MDSC subsets, especially when compared to healthy controls. 
This confirms results from past studies (31) and emphasises the effect the virus has on the 
human immune system. As MDSCs are known to be capable of suppressing T cell functions, 
they might directly affect the immune system’s functions and may contribute to the exhaustion 
which can be seen during an advanced stage of the infection. (see 4.2.4) 
4.2 Cytotoxic T cell response 
This study evaluated the breadth and magnitude of CD8 T cell responses on an epitope level. 
From an array of possible epitopes, Gag and Nef were chosen for study purposes as they are 
known to be two of the most recognised HIV-1 proteins. Therefore, results only reflect immune 
responses to those proteins. It also needs to be noted that continuous HIV treatment has been 
shown to result in a reduction of both, breadth and magnitude of CD8 T cells responses. (53) 
Amongst the study participants under antiretroviral treatment, the NE cohort had continuously 
taken the 5-drug regimen for at least 7 years and the 3ART patients were under conventional 
treatment for at least 4 years. Furthermore, results of CD8 T cell responses were considered for 
detection of possible correlations between the immunosuppressive cells investigated in this 
study. 
4.2.1 No difference of the CD8 T cell response between the intensified treatment group (NE) 
compared to the conventional cART group 
NE patients showed broad responses towards the epitopes of this study. The number of 
responses is comparable to the other HIV groups, in particular to the patients receiving cART 
and implies that there is no difference between the two treatment strategies. 
In contrast, NE patients` immune responses appeared to be slightly stronger than the responses 
patients showed under a conventional HIV treatment, but this difference was only a trend and 
did not reach statistical significance. However, it might imply that preservation of immune 
responses is better when using an intensified treatment strategy.  
4.2.2 An early HIV treatment results in a narrower immune response  
The NE cohort showed immune responses which were similarly broad to those of the other HIV 
groups. Nevertheless, differences in breadth were found between PHI and CHI patients. 




This shows that early treatment intervention can lead to a narrower immune response; most 
likely due to fact that early treatment intervention prevents CD8 T cells to be exposed to the 
HIV antigen for a long period and allows less time to react to the antigen.  
This is also consistent with the findings of a study conducted by Streeck et al who showed that 
a broad CD8 T cell response was associated with a delayed initiation of cART. (60) The overall 
breadth and magnitude can, however, not be taken as predictors for HIV-1 progression. (53) 
The specific response to certain HIV epitopes appears to be rather important in disease 
progression. Streeck et al also showed that disease outcome is better when Gag is getting 
recognised well during primary infection. Besides Gag, the response to the HIV epitope Nef 
has been linked to slower disease progression. (8) Furthermore, Radebe et al showed that the 
point of time when the HIV epitope is recognised is essential: it appears that responses to Nef 
are important in the very early course of infection whereas responses to Gag seem to be crucial 
in the maintenance of HIV at a later stage. (61) 
4.2.3 Recognition of the epitopes Gag and Nef amongst HIV patients 
In this study, Gag p24 and Nef were recognised the most by the HIV groups of this study 
whereas Gag p15 and p17 were less recognised. This is coherent with findings of other groups 
and is likely due to the fact that both epitopes, Gag p24 and Nef, are known to be highly 
immunogenic because of their long and mostly conserved amino acid sequences while Gag p15 
and p17 are shorter and more variable in sequence. (62; 63) The varying responses between the 
single epitopes underline the importance of evaluating the specificity of the CD8 T cell 
response. Clear differences between individual HIV proteins have also been described in a study 
by Kiepiela et al who looked at the viral load of untreated HIV patients and found that it 
correlated inversely with the breadth of T cell responses towards Gag. (64) In contrast, they 
found a direct correlation of the viral load with the breadth of Env-specific T cell responses. An 
interesting study by Mothe et al considered the entire proteome of HIV in 950 patients. Based 
on cohort-level associations with the viral load, they identified several epitopes to be protective 
or non-protective. Among others, protective epitopes appeared in regions of Gag whereas Nef 
was associated with increased viral loads and was thereby described as non-protective. 
Moreover, they could link the protective epitopes with a higher degree of conservation whereas 
non-protective epitopes were less conserved in sequence. The highly conserved sequences also 
appeared to be more stable towards possible viral escape mutations. This is likely to be a 




The results of this study show the state of HIV-specific CD8 T cell responses several years after 
5-drug cART had been initiated in NE patients. Therefore, it is difficult to compare these to 
results from study groups who had drawn blood from untreated patients during their early phase 
of infection. Although a paper by Poizot-Martin et al showed that the long-term application 
does not affect CD8 T cell counts, the question remains whether the responses specifically to a 
certain HIV epitope remain correspondingly. (66) Smith et al compared primed responses of 
naïve CD8 T cells with responses from memory CD8 T cells of HIV patients which had been 
exposed to cART for a substantial amount of time. (67) They showed that those cells were less 
potent in responding to HIV epitopes than their primed naïve counterparts suggesting that CD8 
T cells can lose their ability to respond to HIV epitopes over the course of an antiretroviral 
treatment. Whether or not this loss occurs towards the whole range of HIV epitopes or rather to 
a specific subset of epitopes continues to be subject of research.  
4.2.4 Immune exhaustion during the advanced stage of an HIV infection 
In chronic progressors (PR) the CD8 T cell responses are neither strong nor broad when 
compared to other HIV groups of this study. Conversely, MDSC frequencies are significantly 
elevated. MDSCs are known to be capable of inhibiting functions of CD8 T cells and the lack 
of HIV treatment over a long time has likely led to a certain degree of immune exhaustion in 
the PR group. In contrast to CD4 T cells which decrease early in an untreated HIV infection, 
CD8 T cell frequencies typically remain high until they deplete during later stages of the 
disease. In the absence of cART, CD8 T cells of PR also lose their effector functions and their 
ability to respond to HIV adequately over time. (68) Overall, this emphasises the importance of 




4.3  Limitations of the study 
4.3.1 Different approaches on investigating MDSCs 
MDSCs are a group of immune cells which have been subject to intense research in recent 
years. However, the approach to investigate this distinct cell group differed among research 
groups. It particularly accounts for the used staining techniques to target surface antigens as 
well as intracellular targets. This can primarily be observed in cancer research and needs to be 
considered in comparative analyses of MDSCs. Besides phenotyping, differing gating strategies 
can have a great influence on the results obtained from flow cytometry. Therefore, attempts 
have been made to establish a common gating strategy as a reference for future studies which 
is according to Bronte et al. (29) 
When comparing our study results to results of papers of the past, it must be noted that the 
methods used to isolate PBMC varied amongst research groups. Several groups first froze 
isolated cells and thawed them prior analysis. Grützner et al showed that the kinetics 
particularly in regard to M-MDSCs needs to be carefully taken into account. When isolating 
PBMCs from peripheral blood, M-MDSCs need to be analysed in a fresh state and isolation 
should not be performed later than 4 hrs after blood draw. Otherwise, frequencies will decrease 
significantly. (28) However, this was observed in this study.  
Finally, this thesis has only focused on human MDSCs and the HIV-specific CD8 T cell 
response in peripheral blood. Although most research has been carried out on PBMCs, HIV 
replication mostly occurs in other tissues such as the lymphoid or mucosal tissue. MDSCs are 
usually maintained in the bone marrow under normal conditions and migrate into a number of 
other compartments in response to an infection, i.e. an infection with HIV. Amongst those 
compartments are immunological tissue sites such as the spleen and lymph nodes. Within the 
tumour microenvironment of mouse models, it was demonstrated that localization impacts fate 
as well as function of MDSC. (69) Furthermore, mechanisms of activation as well as their own 
mechanisms of immunosuppression can vary depending on the tissue site and the conditions 
the tissue is facing in that particular moment. Altogether, these results highlight the need for 






4.3.2 Effects of age and gender on HIV progression 
In medicine, it is a well-established concept that age, gender and race of an individual can play 
a role in acquiring a disease and in its progression. Regarding age, multiple studies have shown 
that HIV acts differently in different age groups. In elderly HIV patients, disease progress is 
faster and their recovery under cART is slower than in younger adults. This is most likely 
explained by the aging of the immune system itself which leads to a change in distribution and 
competence of immune cells. (70) This ultimately results in a dysfunctional immune system in 
the elderly. In relation to the frequency of MDSCs, Verschoor et al first showed that MDSC 
frequency is increased with age. Interestingly, this was the case particularly for the PMN-
MDSC subset. (71) 
Similarly, the gender of an individual can change susceptibility, progression, drug response and 
disease outcome. More recent studies found clear differences in clinical characteristics between 
the two genders: Women tend to have significantly lower viral loads than their male 
counterparts when first diagnosed with HIV. Despite their low viral loads, they reach the final 
stages of the HIV infection in about the same time as men. (72) As far as we know there is no 
data on gender and its effect on immunosuppressive cells in HIV patients. Nevertheless, it needs 
to be considered as a potential factor in determining frequencies and functions of 
immunosuppressive cells.  
In the New Era Study, the patients‘ age ranged from 32 to 62 years at the time of blood draw. 
This range was even bigger in the control groups with a range from 20 to 70 years and might 
have impacted the results in terms of immunological aging. In terms of gender, the majority of 
NE patients were male (n= 16) and the 3ART group only consisted of male patients. 
Contrastingly, there was a higher number of women (n= 6) included in the remaining HIV 
groups and in particular in the healthy controls. This needs to be considered when comparing a 









4.3.3 An additional control group: Primary infected HIV patients 
To understand disease progress on a cellular and molecular level, it is necessary to know the 
typical conditions at the very beginning of an HIV infection. In a study by Zhang et al released 
in 2017, it was found that primary infected individuals showed high frequencies of                 
PMN-MDSC which were functionally related to the suppression of CD8 T cells via the ligand 
PD-L1. (38) Thus, it would have been very interesting to compare the obtained results of 
immunosuppressive cells with HIV patients during primary infection. Nonetheless, this study 
included a unique set of HIV patients and gives first insights into immunosuppression at a 
cellular level during an intensified drug regimen.  
4.4 Debate on Treatment interruption in the New Era cohort 
This study was performed to monitor the status of immunosuppressive cells in the NE cohort 
with the aim to identify markers that could potentially help in the process of decision making 
on whether treatment should be interrupted or not in the NE patients. Nonetheless, this topic is 
being debated amongst clinicians, researchers and other HIV experts. On the one hand 
discontinuation of cART is known to be associated with a poor outcome for the patients. This, 
however, applies mostly to long-term discontinuation or repeated cycles of treatment 
interruption. On the other hand, a recent study by Clarridge et al found that a short interval of 
cART interruption did not exert adverse effects on the HIV cohort studied. (73) This suggests 
that a pause from the antiretroviral treatment for a limited amount of time and simultaneously 
frequent clinical controls in short intervals might be ethically acceptable and could give more 
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